Stanford Scientists Unveil AI-Discovered Peptide That Replicates GLP-1 Benefits Without Side Effects
Stanford Medicine researchers have identified a naturally occurring 12‑amino‑acid peptide, BRP, that mimics the appetite‑suppressing effects of semaglutide (Ozempic) while sidestepping common side effects. The discovery, powered by an AI tool called Peptide Predictor, showed weight‑loss and glucose‑control benefits in mice and minipigs without nausea or digestive issues, positioning BRP as a potential safer alternative for metabolic biohackers.
IDEAYA Biosciences Shows 58% Reduction in Disease Progression in Late‑Stage Uveal Melanoma Trial
IDEAYA Biosciences and Servier announced that their Phase II/III OptimUM‑02 trial of darovasertib combined with crizotinib reduced disease‑progression risk by 58% in first‑line HLA‑A*02:01‑negative metastatic uveal melanoma. The combination achieved a median progression‑free survival of 6.9 months versus 3.1 months...
TOBY Gets FDA Breakthrough Device Designation for Urine-Based Multi-Cancer Test
TOBY, Inc., a Texas biotech firm, earned FDA Breakthrough Device Designation for its urine‑based multi‑cancer early detection (MCED) test. The designation accelerates clinical validation and could reshape non‑invasive cancer screening.
MiniMed Flexes with Next-Gen Insulin Pump After Spinning Off From Medtronic
MiniMed, the newly independent diabetes business spun out of Medtronic, secured FDA clearance for its next‑generation MiniMed Flex insulin pump within two weeks of its March 2026 IPO. The Flex is a screenless, pocket‑sized device that retains the 300‑unit reservoir...
Vitamin C Alleviates Aging in Cynomolgus Monkeys
Researchers introduced the term “ferro‑aging” to describe iron‑driven lipid peroxidation that accelerates cellular senescence. They showed that excess iron elevates ACSL4, boosting reactive oxygen species and aging markers in cells, mice and cynomolgus monkeys. A high‑throughput screen identified vitamin C as...
Graphene‑Oxide Nanoplatform Merges Proteasome Inhibition and Phototherapy for Oral Cancer
Scientists have introduced a graphene‑oxide‑based nanoplatform that simultaneously delivers proteasome inhibitors and phototherapy to oral cancer cells. Preclinical tests indicate the combined approach outperforms each modality alone, offering a potential route to more precise, less toxic treatment.
Digital Twin Process Could Slash Microbial Protein Costs
A consortium led by Novasign has built an end‑to‑end digital twin of the microbial protein production process, promising to cut experimental runs by roughly 70% compared with traditional design‑of‑experiments approaches. The model spans upstream to downstream steps, offering real‑time deviation...
Ultra- and Diafiltration Clear Leachables Effectively
A new study from the National Institute for Bioprocessing Research demonstrates that ultrafiltration and diafiltration (UF/DF) consistently remove over 98% of 24 out of 28 tested leachable compounds across three distinct protein processes. The clearance is largely driven by the...
IPSC-Based Manufacture Vs. Autologous Model Production Costs Examined via Financial Analysis
A new Cellistic white paper quantifies the cost advantage of using induced pluripotent stem cells (iPSCs) to manufacture NK cell therapies. The analysis shows cost of goods per dose can drop to roughly $5,000, a 95% reduction compared with $115,000...
Obsidian Therapeutics Merges with Galera in $350M Reverse Deal, Launches OBX Nasdaq Listing
Obsidian Therapeutics and Galera Therapeutics have sealed a reverse merger that includes a $350 million private placement, creating a new Nasdaq‑listed entity under the ticker OBX. The deal gives the combined platform expanded capital and a broader cell‑therapy pipeline, positioning it...
Biopharma Adopting AI Despite Remaining GMP Compliance Questions
Biopharma firms are rapidly integrating artificial intelligence and machine learning into manufacturing, but regulatory‑compliant use cases remain a hurdle. Thermo Fisher’s senior director emphasizes that AI should augment, not replace, validated processes and must operate within a clear GMP framework....
This Pill May Help Pancreatic Cancer Patients Live Longer
Revolution Medicines announced that its RAS‑blocking pill daraxonrasib more than doubled median overall survival for patients with metastatic pancreatic cancer, extending it to 13.2 months versus 6.7 months on chemotherapy. The data will support an expedited FDA filing, and the...
In Vivo Autoimmune CAR-T Race Grows as Two RNA Startups Enter the Clinic
Two RNA‑focused biotech firms have entered human trials of in vivo CAR‑T therapies targeting autoimmune diseases. China’s Immorna reported its first systemic sclerosis patient treated with an RNA‑delivered CAR‑T that reduced peripheral B‑cell activity. A U.S. startup, GeneCure, launched a...
US FDA to Convene Expert Panel to Review Wider Access to some Peptides
The U.S. Food and Drug Administration announced it will convene an external advisory panel in July to decide whether licensed compounding pharmacies can resume manufacturing more than half a dozen peptides that were barred in 2023. The ban covered 14...
Watching A Potential Big Pharma Buyout
A seasoned trader has flagged a small‑cap biotech that checks the key boxes big pharma seeks in an acquisition: late‑stage clinical validation, an imminent FDA decision, a multi‑billion‑dollar addressable market, and a cash‑rich balance sheet. The company’s lead asset is...
Former FDA Cancer Chief Pazdur Warns of the Political 'Breach' Of Review Teams
Richard Pazdur, who led the FDA’s oncology review program for more than two decades, stepped down in December after only a few weeks as director of the agency’s Center for Drug Evaluation and Research. In his departure, Pazdur warned that...
AI Designs Lab-Ready Antibodies From Text Prompts
Drug discovery has always meant finding. Screening libraries. Keeping what survives. Semiconductors don't work that way. Neither do aircraft. You design them computationally before anything gets built. @saakohl left @GoogleDeepMind after co-developing AlphaFold2 to do the same thing for biologics. @LatentLabs_ Latent-X2...
Novel Targets for Complex Cancer Revealed by Genetic Regulatory Node Mapping
Researchers at Rockefeller University unveiled PerturbFate, a single‑cell platform that maps how diverse genetic variations reshape cellular behavior over time. By profiling DNA accessibility, RNA output, and chromatin state in thousands of cells, the system identified common regulatory nodes that...
Chinese Biotechs Lead Licensing as M&A Surges
M&A is sizzling right along, with the Q1 numbers looking good for biotech. IPOs got started on the year with a spike in offerings and some mixed results on the Street. Dealmaking remains solid. And shall we just call it...
FDA Peptide Meeting Signals $100B Market Boom
I wish this FDA meeting to discuss peptides was happening a little sooner but I'm glad it's finally on the calendar so we don't have to keep guessing. Looks like they're going to start with 7 peptides (BPC-157, TB-500, KPV, Mots-C,...
Organon’s VTAMA® (Tapinarof) Cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis
Organon announced that its steroid‑free VTAMA® (tapinarof) 1% cream received a strong, evidence‑based recommendation in the American Academy of Dermatology’s 2026 pediatric atopic dermatitis (AD) guidelines. The AAD highlighted VTAMA as the only topical treatment with high‑certainty evidence that is...
Synthetic Biologists' Mirror‑image Microbe Dream Hits Complexity
Synthetic biologists were tantalized by the idea of making mirror images of microbes. Then things got complicated.
Revolution Medicines Prices $2B Raise as XBI Reaches Heights Not Seen Since Pandemic
Revolution Medicines priced a $2 billion public offering, marking the biotech sector’s largest equity raise since the COVID‑19 pandemic. The capital raise follows a recent positive readout from the company’s late‑stage trial, boosting investor confidence. The move helped lift the SPDR...
Two‑Month Dosing Likely Beats Monthly in PK Trial
As I commented before, they have Phase 2 PK data and they still took both 2 months and 3 months into Ph 3. The primary endpoint is purely a PK non-inferiority one (AUC through week 24). That means that 2...
What’s the Deal with Alzheimer’s Disease and Amyloid?
A wave of retractions, including a 2011 Neurobiology of Aging paper, has exposed fabricated data behind the amyloid‑β hypothesis for Alzheimer’s disease. Decades of costly clinical trials targeting amyloid‑β have repeatedly failed to deliver meaningful cognitive benefits, culminating in the...
Pharma Finance Roundup: Platform Innovation Drives Biotech Investment Across Oncology and Immunology
This week’s biotech financing spotlighted platform‑driven innovation in oncology and immunology. Adcendo closed a $75 million Series C to expand its ADC pipeline, while Beeline Medicines launched with $300 million Series A to develop precision autoimmune therapies. Harbinger Health secured $100 million for its multi‑cancer...
Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries
Precision BioSciences received Clinical Trial Application approval to add sites in France and Romania to its global ELIMINATE‑B study of PBGENE‑HBV, an in‑vivo gene‑editing therapy for chronic hepatitis B. The expansion joins existing locations in the United Kingdom, Moldova, New Zealand, Hong Kong...
BIO Launches ‘Fight of Our Lives’: The Real Stories, Power, and Promise of American Biotech at a Defining Moment
The Biotechnology Innovation Organization (BIO) has launched the "Fight of Our Lives" campaign, using real patient narratives to underscore the impact of American biotech. The initiative features three inaugural stories—a rare‑genetic condition treated with targeted gene therapy, the first CAR‑T...
Muscle Atrophy Driven by Intrinsic Aging, Not Nerve Damage
I teach medical students that nerve damage causes muscle wasting. New research says we had it backwards. Scientists at MDI Biological Lab engineered "atrofish" -- zebrafish that compress DECADES of human muscle aging into weeks by activating the Atrogin-1 gene. What they...
Whitepaper: CDMOs at a Crossroads
The contract development and manufacturing organization (CDMO) sector is undergoing a rapid transformation as pharma and biotech firms chase end‑to‑end solutions for biologics, cell and gene therapies. Demand for specialized partnerships is rising alongside U.S. policies that encourage domestic production....
WSJ Defends Replimune Drug Amid Mounting Criticism
@WSJ is not giving up the fight for Replimune's cancer drug. Second CRL draws another rebuke and a direct attack on @MartyMakary (Prasad gets another swipe as well, but he's about out the door now.) I often disagree with the...
Electromagnetic Gene Switch Extends Lifespan in Progeroid Mice
Wow, a technique that allows electromagnetic control of gene expression in vivo 🤯 And they tested their system with OSK partial reprogramming, showing it extends lifespan in progeroid mice. In normal mice, they report health improvements and a small reduction in mortality...
Life Biosciences Prepares First Human Trial of Partial Cellular Reprogramming for Glaucoma
Life Biosciences, co‑founded by David Sinclair, is preparing to launch the first human trial of partial cellular reprogramming, targeting retinal nerve cells in glaucoma patients. The study will use a three‑factor gene‑delivery system that can be switched on and off...
Liquid AI Launches Foundation Model for Drug Discovery
@semafor World Economy brought together most of the global CEOs to Washington, DC. And it is a pleasure and honor to meet our amazing partner @ramin_m_h of Liquid AI . We just published the Liquid Foundation Model capable...
Promolytics: Targeting Cancer‑Promoting Clones to Halt Progression
A new review on tumor promotion and the evolution of cancer with the concept of "promolytics" —drugs that could prevent potentially dangerous clones and/or their progression https://t.co/IFah5gi8ZK @Nature
Novo Nordisk Teams Up with OpenAI to Fast‑Track Obesity Drug Development
Novo Nordisk announced a strategic partnership with OpenAI to embed advanced AI across its research pipeline, aiming to shorten development time for obesity and diabetes treatments. The deal, disclosed on April 14, sent Novo’s shares up 2.8% and underscores a...
Moderna's Cancer Therapy Rename May Mislead Physicians
Moderna mRNA cancer treatment used to be called a "cancer vaccine" but in 2023 they switched to "individualized neoantigen therapy." Some docs think the name change is misleading. https://t.co/UIn2djdDAv
AI Agents Power Future Biotech Labs and Organizations
Live in 15 minutes — I'm talking with Stanford's @james_y_zou on his latest research in building laboratories and biotech orgs made of hundreds or even thousands of AI agents Register now to watch live, for free: https://t.co/xSa5NXkX4A
Obsidian, Galera to Advance Cell Therapy Following Reverse Merger
Obsidian Therapeutics will go public on Nasdaq via a reverse merger with Galera Therapeutics, creating a combined entity focused on OBX-115, a tumor‑infiltrating lymphocyte (TIL) cell therapy. OBX-115 is in mid‑stage melanoma and early‑stage lung‑cancer trials and is designed to...
Statins Don't Harm Muscle Health in Older Adults
Statin use does not impair muscle health in older adults: findings from the SCOPE study https://t.co/WKjk9Ov0rG https://t.co/xTo9mk3vbw
FDA Panel to Consider Expanding Peptide Access
FDA panel will meet to discuss allowing broader access to certain peptides https://t.co/PDWKvmvvUH via @LizzyLaw_
BMS Makes a Beeline, Bringing 5 Assets to Biotech's $300M Precision Immunology Debut
Bristol Myers Squibb has spun out a new biotech, Beeline Medicines, backed by $300 million from Bain Capital and an initial portfolio of five assets. The company, led by former SpringWorks CEO Saqib Islam, will focus on precision therapies for autoimmune...
AI-Driven Global Collaboration Needed for Longevity Research
Great speaking with @SpeakerPelosi at @semafor . In my opinion, drug discovery for cancer and age-related diseases should be a global effort. Nations need to strive to collaborate to extend healthy productive life. Please through longevity. It is the best...
STAT+: Pharmalittle: We’re Reading About FDA Seeking More Data on a Lilly Obesity Pill, a Pharma 340B Win, and More
U.S. FDA has asked Eli Lilly to provide additional safety data on its newly approved obesity drug Foundayo, mandating post‑marketing trials for cardiovascular events, delayed gastric emptying, and a lactation study. The pill, a GLP‑1 agonist, received accelerated approval through the...
Replimune Shares Tumble 64% After FDA Issues Second CRL on RP1 Vaccine
Replimune's shares dropped about 64% on April 10 after the FDA issued a second Complete Response Letter rejecting the RP1 vaccine. The setback forces the company into job cuts, raises questions about its pivotal IGNYTE‑3 trial, and slashes analyst price...
Eight Allergy Companies to Watch in 2026
The allergy‑treatment landscape is moving from symptom relief to disease‑modifying therapies, with eight biotech firms leading the charge in 2026. Allergy Therapeutics secured German approval for its short‑course Grassmuno vaccine, while Aravax bolstered its board ahead of a phase 3 launch...
Ads for GLP-1 Drugs Are Flooding the Internet – Here’s How to Know if It’s Safe to Buy Them Online
The surge in online advertisements for GLP‑1 weight‑loss drugs, amplified by a high‑profile Super Bowl commercial, has led many consumers to seek cheaper, compounded versions of medications like Ozempic and Wegovy. The FDA warns that these non‑brand products often bypass...
New Technique Maps Cancer Drug Uptake Inside Living Cells
Researchers at the University of Surrey and King's College London have unveiled a new analytical workflow that maps metal‑based cancer drugs inside living cells. By pairing SEISMIC capillary sampling with laser‑ablation ICP‑MS, they detected trace thallium—used as a surrogate for...
Australian Bee Glue Delivers a Scar-Fighting Compound that Shuts Down Raised Scars Before They Take Hold
University of the Sunshine Coast researchers have isolated a natural compound, tomentosenol A, from the propolis of the Australian stingless bee Tetragonula carbonaria. Laboratory tests on human skin cells showed the molecule blocks scar‑forming signals and induces fibroblast self‑destruction, mimicking normal...
AI Agents and Next‑Gen Alzheimer’s Drugs Beyond CRISPR
Endpoints' Drug Discovery Day is today — our own @RLCscienceboss will be talking about beyond CRISPR & future of Alzheimer's drugs I'm excited to talk with Stanford's @james_y_zou on his escalating research in building AI agents into co-scientists, labs, and now biotechs...